A leading research institution wished to evaluated a promising new scaffold technology for potential investment. We assisted in a structured process of identifying a wide range of potential tissue repair opportunities, and assessing the potential market size, and cost and time to market.
The commercial arm of a leading research institution wished to evaluated a promising new scaffold technology for potential investment. We assisted in a structured process of identifying a wide range of potential opportunities that included autologous and allogeneic cell therapies for tissue repair and regeneration. These were assessed for market potential and ease of development through to a product in order to rank the opportunities on their attractiveness for investment. Further detailed analysis was then done on the top ranking opportunities to assess market size, and likely cost and timescales through to a commercial product. This involved both primary analysis using our network of clinicians and other stakeholders, and secondary data obtained from desk research. We also reviewed likely regulatory routes for the different opportunities ranging from products classed as medicines, through to biologics, combination devices and medical devices. The route clearly impacted heavily on the likely cost of taking a product to market.
We are a specialist medical device consultancy consisting of industry experts with long and successful track records in commercialising medical device products. We have broad functional and sector experience, and would welcome an opportunity to discuss with you any challenge relating to creating sustainable value from medical technologies.
Our consultant Munna Choudhury attended the FierceBiotech Executive Summit in London on
Munna Choudhury of Alacramed will be attending the Fierce Biotech UK Summit on
Mark Wickham of Alacramed will be attending Med-Tech Innovation Innovation Expo 2018 at
Alacramed Ltd, St Johns Innovation Centre, Cowley Road, Cambridge,
+44 (0) 1223 421885